nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—SLCO1B3—Methotrexate—esophageal cancer	0.269	0.372	CbGbCtD
Valsartan—SLCO1B1—Methotrexate—esophageal cancer	0.156	0.216	CbGbCtD
Valsartan—CYP2C9—Capecitabine—esophageal cancer	0.141	0.195	CbGbCtD
Valsartan—ALB—Methotrexate—esophageal cancer	0.0857	0.118	CbGbCtD
Valsartan—CYP2C9—Cisplatin—esophageal cancer	0.0711	0.0984	CbGbCtD
Valsartan—Renal failure chronic—Cisplatin—esophageal cancer	0.00702	0.0507	CcSEcCtD
Valsartan—Dry cough—Methotrexate—esophageal cancer	0.00671	0.0484	CcSEcCtD
Valsartan—Olmesartan—ABCC2—esophageal cancer	0.00332	0.378	CrCbGaD
Valsartan—Serum creatinine increased—Cisplatin—esophageal cancer	0.00308	0.0222	CcSEcCtD
Valsartan—Ageusia—Cisplatin—esophageal cancer	0.00234	0.0168	CcSEcCtD
Valsartan—Infection—Carboplatin—esophageal cancer	0.00229	0.0165	CcSEcCtD
Valsartan—Serum creatinine increased—Capecitabine—esophageal cancer	0.00227	0.0164	CcSEcCtD
Valsartan—Loss of libido—Methotrexate—esophageal cancer	0.00225	0.0162	CcSEcCtD
Valsartan—Candesartan—PTGS1—esophageal cancer	0.00195	0.222	CrCbGaD
Valsartan—Irbesartan—PTGS1—esophageal cancer	0.00195	0.222	CrCbGaD
Valsartan—Hyperkalaemia—Cisplatin—esophageal cancer	0.00186	0.0134	CcSEcCtD
Valsartan—Ageusia—Capecitabine—esophageal cancer	0.00172	0.0124	CcSEcCtD
Valsartan—Renal failure acute—Cisplatin—esophageal cancer	0.00149	0.0107	CcSEcCtD
Valsartan—Blood pressure increased—Capecitabine—esophageal cancer	0.00139	0.0101	CcSEcCtD
Valsartan—Hyponatraemia—Cisplatin—esophageal cancer	0.00138	0.00995	CcSEcCtD
Valsartan—Blood creatinine increased—Cisplatin—esophageal cancer	0.00129	0.00928	CcSEcCtD
Valsartan—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00125	0.00905	CcSEcCtD
Valsartan—Cramp muscle—Cisplatin—esophageal cancer	0.00124	0.00892	CcSEcCtD
Valsartan—Photosensitivity—Capecitabine—esophageal cancer	0.00115	0.00832	CcSEcCtD
Valsartan—Swelling—Capecitabine—esophageal cancer	0.00115	0.00828	CcSEcCtD
Valsartan—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.0011	0.00792	CcSEcCtD
Valsartan—Renal failure acute—Capecitabine—esophageal cancer	0.0011	0.00791	CcSEcCtD
Valsartan—Atrial fibrillation—Capecitabine—esophageal cancer	0.00107	0.00771	CcSEcCtD
Valsartan—Renal impairment—Capecitabine—esophageal cancer	0.00106	0.00767	CcSEcCtD
Valsartan—Vasculitis—Methotrexate—esophageal cancer	0.00106	0.00767	CcSEcCtD
Valsartan—Dermatitis bullous—Capecitabine—esophageal cancer	0.00106	0.00764	CcSEcCtD
Valsartan—Renal failure—Cisplatin—esophageal cancer	0.00104	0.0075	CcSEcCtD
Valsartan—Cardiac failure—Capecitabine—esophageal cancer	0.00104	0.00748	CcSEcCtD
Valsartan—Hyponatraemia—Capecitabine—esophageal cancer	0.00102	0.00733	CcSEcCtD
Valsartan—Candesartan—ABCB1—esophageal cancer	0.00095	0.108	CrCbGaD
Valsartan—Blood creatinine increased—Capecitabine—esophageal cancer	0.000948	0.00684	CcSEcCtD
Valsartan—Urinary tract disorder—Cisplatin—esophageal cancer	0.000938	0.00677	CcSEcCtD
Valsartan—Connective tissue disorder—Cisplatin—esophageal cancer	0.000934	0.00673	CcSEcCtD
Valsartan—Urethral disorder—Cisplatin—esophageal cancer	0.000931	0.00672	CcSEcCtD
Valsartan—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000925	0.00667	CcSEcCtD
Valsartan—Abdominal pain upper—Capecitabine—esophageal cancer	0.000925	0.00667	CcSEcCtD
Valsartan—Muscular weakness—Capecitabine—esophageal cancer	0.000893	0.00644	CcSEcCtD
Valsartan—Cardiac disorder—Cisplatin—esophageal cancer	0.000882	0.00636	CcSEcCtD
Valsartan—Photosensitivity—Methotrexate—esophageal cancer	0.000858	0.00619	CcSEcCtD
Valsartan—Immune system disorder—Cisplatin—esophageal cancer	0.000858	0.00619	CcSEcCtD
Valsartan—Mediastinal disorder—Cisplatin—esophageal cancer	0.000856	0.00618	CcSEcCtD
Valsartan—Bronchitis—Capecitabine—esophageal cancer	0.000841	0.00607	CcSEcCtD
Valsartan—Alopecia—Cisplatin—esophageal cancer	0.000839	0.00606	CcSEcCtD
Valsartan—Malnutrition—Cisplatin—esophageal cancer	0.000827	0.00597	CcSEcCtD
Valsartan—Neutropenia—Capecitabine—esophageal cancer	0.000818	0.0059	CcSEcCtD
Valsartan—Renal failure acute—Methotrexate—esophageal cancer	0.000816	0.00589	CcSEcCtD
Valsartan—Flatulence—Cisplatin—esophageal cancer	0.000815	0.00588	CcSEcCtD
Valsartan—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000813	0.00587	CcSEcCtD
Valsartan—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000799	0.00576	CcSEcCtD
Valsartan—Muscle spasms—Cisplatin—esophageal cancer	0.000795	0.00574	CcSEcCtD
Valsartan—Infestation NOS—Capecitabine—esophageal cancer	0.00078	0.00563	CcSEcCtD
Valsartan—Infestation—Capecitabine—esophageal cancer	0.00078	0.00563	CcSEcCtD
Valsartan—Vision blurred—Cisplatin—esophageal cancer	0.000779	0.00562	CcSEcCtD
Valsartan—Renal failure—Capecitabine—esophageal cancer	0.000767	0.00553	CcSEcCtD
Valsartan—Epistaxis—Capecitabine—esophageal cancer	0.000736	0.00531	CcSEcCtD
Valsartan—Myalgia—Cisplatin—esophageal cancer	0.000704	0.00508	CcSEcCtD
Valsartan—Haemoglobin—Capecitabine—esophageal cancer	0.000704	0.00508	CcSEcCtD
Valsartan—Rhinitis—Capecitabine—esophageal cancer	0.000702	0.00506	CcSEcCtD
Valsartan—Anxiety—Cisplatin—esophageal cancer	0.000702	0.00506	CcSEcCtD
Valsartan—Hepatitis—Capecitabine—esophageal cancer	0.0007	0.00505	CcSEcCtD
Valsartan—Haemorrhage—Capecitabine—esophageal cancer	0.0007	0.00505	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000699	0.00504	CcSEcCtD
Valsartan—Pharyngitis—Capecitabine—esophageal cancer	0.000695	0.00501	CcSEcCtD
Valsartan—Urinary tract disorder—Capecitabine—esophageal cancer	0.000692	0.00499	CcSEcCtD
Valsartan—Connective tissue disorder—Capecitabine—esophageal cancer	0.000688	0.00496	CcSEcCtD
Valsartan—Urethral disorder—Capecitabine—esophageal cancer	0.000686	0.00495	CcSEcCtD
Valsartan—Oedema—Cisplatin—esophageal cancer	0.000675	0.00487	CcSEcCtD
Valsartan—Anaphylactic shock—Cisplatin—esophageal cancer	0.000675	0.00487	CcSEcCtD
Valsartan—Infection—Cisplatin—esophageal cancer	0.000671	0.00484	CcSEcCtD
Valsartan—Nervous system disorder—Cisplatin—esophageal cancer	0.000662	0.00478	CcSEcCtD
Valsartan—Thrombocytopenia—Cisplatin—esophageal cancer	0.000661	0.00477	CcSEcCtD
Valsartan—Skin disorder—Cisplatin—esophageal cancer	0.000656	0.00473	CcSEcCtD
Valsartan—Cardiac disorder—Capecitabine—esophageal cancer	0.00065	0.00469	CcSEcCtD
Valsartan—Anorexia—Cisplatin—esophageal cancer	0.000643	0.00464	CcSEcCtD
Valsartan—Angiopathy—Capecitabine—esophageal cancer	0.000635	0.00458	CcSEcCtD
Valsartan—Immune system disorder—Capecitabine—esophageal cancer	0.000633	0.00456	CcSEcCtD
Valsartan—Mediastinal disorder—Capecitabine—esophageal cancer	0.000631	0.00455	CcSEcCtD
Valsartan—Hypotension—Cisplatin—esophageal cancer	0.000631	0.00455	CcSEcCtD
Valsartan—Alopecia—Capecitabine—esophageal cancer	0.000619	0.00446	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000615	0.00444	CcSEcCtD
Valsartan—Mental disorder—Capecitabine—esophageal cancer	0.000614	0.00443	CcSEcCtD
Valsartan—Losartan—ABCB1—esophageal cancer	0.000612	0.0696	CrCbGaD
Valsartan—Malnutrition—Capecitabine—esophageal cancer	0.00061	0.0044	CcSEcCtD
Valsartan—Neutropenia—Methotrexate—esophageal cancer	0.000609	0.00439	CcSEcCtD
Valsartan—Paraesthesia—Cisplatin—esophageal cancer	0.000606	0.00437	CcSEcCtD
Valsartan—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000605	0.00437	CcSEcCtD
Valsartan—Dyspnoea—Cisplatin—esophageal cancer	0.000602	0.00434	CcSEcCtD
Valsartan—Flatulence—Capecitabine—esophageal cancer	0.000601	0.00433	CcSEcCtD
Valsartan—Erectile dysfunction—Methotrexate—esophageal cancer	0.0006	0.00433	CcSEcCtD
Valsartan—Dysgeusia—Capecitabine—esophageal cancer	0.000597	0.00431	CcSEcCtD
Valsartan—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000594	0.00429	CcSEcCtD
Valsartan—Back pain—Capecitabine—esophageal cancer	0.00059	0.00425	CcSEcCtD
Valsartan—Decreased appetite—Cisplatin—esophageal cancer	0.000587	0.00423	CcSEcCtD
Valsartan—Muscle spasms—Capecitabine—esophageal cancer	0.000586	0.00423	CcSEcCtD
Valsartan—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000583	0.0042	CcSEcCtD
Valsartan—Infestation NOS—Methotrexate—esophageal cancer	0.000581	0.00419	CcSEcCtD
Valsartan—Infestation—Methotrexate—esophageal cancer	0.000581	0.00419	CcSEcCtD
Valsartan—Vision blurred—Capecitabine—esophageal cancer	0.000575	0.00414	CcSEcCtD
Valsartan—Renal failure—Methotrexate—esophageal cancer	0.000571	0.00412	CcSEcCtD
Valsartan—Epistaxis—Methotrexate—esophageal cancer	0.000548	0.00395	CcSEcCtD
Valsartan—Vertigo—Capecitabine—esophageal cancer	0.000548	0.00395	CcSEcCtD
Valsartan—Syncope—Capecitabine—esophageal cancer	0.000547	0.00394	CcSEcCtD
Valsartan—Palpitations—Capecitabine—esophageal cancer	0.000539	0.00389	CcSEcCtD
Valsartan—Loss of consciousness—Capecitabine—esophageal cancer	0.000536	0.00387	CcSEcCtD
Valsartan—Cough—Capecitabine—esophageal cancer	0.000532	0.00384	CcSEcCtD
Valsartan—Haemoglobin—Methotrexate—esophageal cancer	0.000524	0.00378	CcSEcCtD
Valsartan—Haemorrhage—Methotrexate—esophageal cancer	0.000521	0.00376	CcSEcCtD
Valsartan—Hepatitis—Methotrexate—esophageal cancer	0.000521	0.00376	CcSEcCtD
Valsartan—Chest pain—Capecitabine—esophageal cancer	0.000519	0.00374	CcSEcCtD
Valsartan—Myalgia—Capecitabine—esophageal cancer	0.000519	0.00374	CcSEcCtD
Valsartan—Arthralgia—Capecitabine—esophageal cancer	0.000519	0.00374	CcSEcCtD
Valsartan—Pharyngitis—Methotrexate—esophageal cancer	0.000517	0.00373	CcSEcCtD
Valsartan—Anxiety—Capecitabine—esophageal cancer	0.000517	0.00373	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000515	0.00372	CcSEcCtD
Valsartan—Urinary tract disorder—Methotrexate—esophageal cancer	0.000515	0.00371	CcSEcCtD
Valsartan—Urethral disorder—Methotrexate—esophageal cancer	0.000511	0.00369	CcSEcCtD
Valsartan—Dry mouth—Capecitabine—esophageal cancer	0.000508	0.00366	CcSEcCtD
Valsartan—Oedema—Capecitabine—esophageal cancer	0.000498	0.00359	CcSEcCtD
Valsartan—Hypersensitivity—Cisplatin—esophageal cancer	0.000497	0.00359	CcSEcCtD
Valsartan—Infection—Capecitabine—esophageal cancer	0.000494	0.00357	CcSEcCtD
Valsartan—Shock—Capecitabine—esophageal cancer	0.000489	0.00353	CcSEcCtD
Valsartan—Nervous system disorder—Capecitabine—esophageal cancer	0.000488	0.00352	CcSEcCtD
Valsartan—Thrombocytopenia—Capecitabine—esophageal cancer	0.000487	0.00351	CcSEcCtD
Valsartan—Asthenia—Cisplatin—esophageal cancer	0.000484	0.00349	CcSEcCtD
Valsartan—Cardiac disorder—Methotrexate—esophageal cancer	0.000484	0.00349	CcSEcCtD
Valsartan—Skin disorder—Capecitabine—esophageal cancer	0.000483	0.00349	CcSEcCtD
Valsartan—Anorexia—Capecitabine—esophageal cancer	0.000474	0.00342	CcSEcCtD
Valsartan—Angiopathy—Methotrexate—esophageal cancer	0.000473	0.00341	CcSEcCtD
Valsartan—Immune system disorder—Methotrexate—esophageal cancer	0.000471	0.0034	CcSEcCtD
Valsartan—Mediastinal disorder—Methotrexate—esophageal cancer	0.00047	0.00339	CcSEcCtD
Valsartan—Hypotension—Capecitabine—esophageal cancer	0.000465	0.00335	CcSEcCtD
Valsartan—Diarrhoea—Cisplatin—esophageal cancer	0.000462	0.00333	CcSEcCtD
Valsartan—Alopecia—Methotrexate—esophageal cancer	0.000461	0.00332	CcSEcCtD
Valsartan—Mental disorder—Methotrexate—esophageal cancer	0.000457	0.00329	CcSEcCtD
Valsartan—Malnutrition—Methotrexate—esophageal cancer	0.000454	0.00327	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000453	0.00327	CcSEcCtD
Valsartan—Insomnia—Capecitabine—esophageal cancer	0.00045	0.00325	CcSEcCtD
Valsartan—Paraesthesia—Capecitabine—esophageal cancer	0.000447	0.00322	CcSEcCtD
Valsartan—Dysgeusia—Methotrexate—esophageal cancer	0.000444	0.00321	CcSEcCtD
Valsartan—Dyspnoea—Capecitabine—esophageal cancer	0.000444	0.0032	CcSEcCtD
Valsartan—Back pain—Methotrexate—esophageal cancer	0.000439	0.00317	CcSEcCtD
Valsartan—Dyspepsia—Capecitabine—esophageal cancer	0.000438	0.00316	CcSEcCtD
Valsartan—Decreased appetite—Capecitabine—esophageal cancer	0.000433	0.00312	CcSEcCtD
Valsartan—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00043	0.0031	CcSEcCtD
Valsartan—Vomiting—Cisplatin—esophageal cancer	0.000429	0.0031	CcSEcCtD
Valsartan—Fatigue—Capecitabine—esophageal cancer	0.000429	0.00309	CcSEcCtD
Valsartan—Vision blurred—Methotrexate—esophageal cancer	0.000428	0.00309	CcSEcCtD
Valsartan—Rash—Cisplatin—esophageal cancer	0.000426	0.00307	CcSEcCtD
Valsartan—Constipation—Capecitabine—esophageal cancer	0.000425	0.00307	CcSEcCtD
Valsartan—Dermatitis—Cisplatin—esophageal cancer	0.000425	0.00307	CcSEcCtD
Valsartan—Vertigo—Methotrexate—esophageal cancer	0.000408	0.00294	CcSEcCtD
Valsartan—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000407	0.00294	CcSEcCtD
Valsartan—Nausea—Cisplatin—esophageal cancer	0.000401	0.00289	CcSEcCtD
Valsartan—Cough—Methotrexate—esophageal cancer	0.000396	0.00286	CcSEcCtD
Valsartan—Urticaria—Capecitabine—esophageal cancer	0.000395	0.00285	CcSEcCtD
Valsartan—Abdominal pain—Capecitabine—esophageal cancer	0.000393	0.00284	CcSEcCtD
Valsartan—Arthralgia—Methotrexate—esophageal cancer	0.000386	0.00279	CcSEcCtD
Valsartan—Chest pain—Methotrexate—esophageal cancer	0.000386	0.00279	CcSEcCtD
Valsartan—Myalgia—Methotrexate—esophageal cancer	0.000386	0.00279	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000384	0.00277	CcSEcCtD
Valsartan—Anaphylactic shock—Methotrexate—esophageal cancer	0.00037	0.00267	CcSEcCtD
Valsartan—Infection—Methotrexate—esophageal cancer	0.000368	0.00265	CcSEcCtD
Valsartan—Hypersensitivity—Capecitabine—esophageal cancer	0.000367	0.00264	CcSEcCtD
Valsartan—Nervous system disorder—Methotrexate—esophageal cancer	0.000363	0.00262	CcSEcCtD
Valsartan—Thrombocytopenia—Methotrexate—esophageal cancer	0.000363	0.00262	CcSEcCtD
Valsartan—Skin disorder—Methotrexate—esophageal cancer	0.00036	0.0026	CcSEcCtD
Valsartan—Asthenia—Capecitabine—esophageal cancer	0.000357	0.00258	CcSEcCtD
Valsartan—Anorexia—Methotrexate—esophageal cancer	0.000353	0.00255	CcSEcCtD
Valsartan—Pruritus—Capecitabine—esophageal cancer	0.000352	0.00254	CcSEcCtD
Valsartan—Hypotension—Methotrexate—esophageal cancer	0.000346	0.0025	CcSEcCtD
Valsartan—Diarrhoea—Capecitabine—esophageal cancer	0.00034	0.00246	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000337	0.00243	CcSEcCtD
Valsartan—Insomnia—Methotrexate—esophageal cancer	0.000335	0.00242	CcSEcCtD
Valsartan—Paraesthesia—Methotrexate—esophageal cancer	0.000333	0.0024	CcSEcCtD
Valsartan—Dyspnoea—Methotrexate—esophageal cancer	0.00033	0.00238	CcSEcCtD
Valsartan—Somnolence—Methotrexate—esophageal cancer	0.000329	0.00238	CcSEcCtD
Valsartan—Dizziness—Capecitabine—esophageal cancer	0.000329	0.00237	CcSEcCtD
Valsartan—Dyspepsia—Methotrexate—esophageal cancer	0.000326	0.00235	CcSEcCtD
Valsartan—Decreased appetite—Methotrexate—esophageal cancer	0.000322	0.00232	CcSEcCtD
Valsartan—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00032	0.00231	CcSEcCtD
Valsartan—Fatigue—Methotrexate—esophageal cancer	0.000319	0.0023	CcSEcCtD
Valsartan—Vomiting—Capecitabine—esophageal cancer	0.000316	0.00228	CcSEcCtD
Valsartan—Rash—Capecitabine—esophageal cancer	0.000314	0.00226	CcSEcCtD
Valsartan—Dermatitis—Capecitabine—esophageal cancer	0.000313	0.00226	CcSEcCtD
Valsartan—Headache—Capecitabine—esophageal cancer	0.000312	0.00225	CcSEcCtD
Valsartan—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000303	0.00218	CcSEcCtD
Valsartan—Nausea—Capecitabine—esophageal cancer	0.000296	0.00213	CcSEcCtD
Valsartan—Urticaria—Methotrexate—esophageal cancer	0.000294	0.00212	CcSEcCtD
Valsartan—Abdominal pain—Methotrexate—esophageal cancer	0.000293	0.00211	CcSEcCtD
Valsartan—Hypersensitivity—Methotrexate—esophageal cancer	0.000273	0.00197	CcSEcCtD
Valsartan—Asthenia—Methotrexate—esophageal cancer	0.000266	0.00192	CcSEcCtD
Valsartan—Pruritus—Methotrexate—esophageal cancer	0.000262	0.00189	CcSEcCtD
Valsartan—Diarrhoea—Methotrexate—esophageal cancer	0.000253	0.00183	CcSEcCtD
Valsartan—Dizziness—Methotrexate—esophageal cancer	0.000245	0.00177	CcSEcCtD
Valsartan—Vomiting—Methotrexate—esophageal cancer	0.000235	0.0017	CcSEcCtD
Valsartan—Rash—Methotrexate—esophageal cancer	0.000234	0.00168	CcSEcCtD
Valsartan—Dermatitis—Methotrexate—esophageal cancer	0.000233	0.00168	CcSEcCtD
Valsartan—Headache—Methotrexate—esophageal cancer	0.000232	0.00167	CcSEcCtD
Valsartan—Nausea—Methotrexate—esophageal cancer	0.00022	0.00159	CcSEcCtD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000181	0.0014	CbGpPWpGaD
Valsartan—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000181	0.0014	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000181	0.0014	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—WWOX—esophageal cancer	0.000179	0.00139	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000176	0.00136	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000176	0.00136	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ADH7—esophageal cancer	0.000174	0.00135	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PLCE1—esophageal cancer	0.000174	0.00135	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000172	0.00133	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—HSPA5—esophageal cancer	0.000172	0.00133	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FKBP1A—esophageal cancer	0.000171	0.00132	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—ANXA1—esophageal cancer	0.000168	0.0013	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000168	0.0013	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—WIF1—esophageal cancer	0.000167	0.00129	CbGpPWpGaD
Valsartan—ALB—Hemostasis—DOCK2—esophageal cancer	0.000165	0.00127	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000165	0.00127	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL2—esophageal cancer	0.000164	0.00127	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—SST—esophageal cancer	0.000163	0.00126	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—BLVRB—esophageal cancer	0.000162	0.00125	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SLC52A3—esophageal cancer	0.000162	0.00125	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—GHRL—esophageal cancer	0.000159	0.00123	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000158	0.00122	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000154	0.00119	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ADH1B—esophageal cancer	0.000153	0.00118	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—ANXA1—esophageal cancer	0.000152	0.00118	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.00015	0.00116	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00015	0.00116	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000149	0.00115	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—SST—esophageal cancer	0.000148	0.00115	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000148	0.00114	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000146	0.00113	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—TYMP—esophageal cancer	0.000146	0.00113	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000145	0.00112	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—GHRL—esophageal cancer	0.000145	0.00112	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000144	0.00112	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PFN1—esophageal cancer	0.000144	0.00111	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000143	0.00111	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000143	0.0011	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PFN1—esophageal cancer	0.000142	0.0011	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP26A1—esophageal cancer	0.000142	0.0011	CbGpPWpGaD
Valsartan—AGTR1—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000142	0.00109	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—PTGS2—esophageal cancer	0.000141	0.00109	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000141	0.00109	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000139	0.00107	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALOX15—esophageal cancer	0.000138	0.00107	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SLC10A2—esophageal cancer	0.000138	0.00106	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CA1—esophageal cancer	0.000138	0.00106	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000137	0.00106	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000137	0.00106	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTO1—esophageal cancer	0.000132	0.00102	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—TPI1—esophageal cancer	0.000132	0.00102	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ELMO1—esophageal cancer	0.000129	0.000999	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000127	0.000979	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALDOB—esophageal cancer	0.000126	0.000977	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKAP13—esophageal cancer	0.000126	0.000977	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CA2—esophageal cancer	0.000126	0.000972	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000123	0.00095	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GAPDH—esophageal cancer	0.000122	0.000941	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CRABP1—esophageal cancer	0.000121	0.000932	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000119	0.000921	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ADH7—esophageal cancer	0.000117	0.000904	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PLCE1—esophageal cancer	0.000117	0.000904	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000117	0.000902	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PDE4D—esophageal cancer	0.000116	0.000893	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000116	0.000893	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CFL1—esophageal cancer	0.000115	0.000891	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GNG7—esophageal cancer	0.000115	0.000887	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GNG7—esophageal cancer	0.00011	0.00085	CbGpPWpGaD
Valsartan—ALB—Hemostasis—GNG7—esophageal cancer	0.000109	0.00084	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALDH2—esophageal cancer	0.000108	0.000831	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TP53—esophageal cancer	0.000106	0.000816	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000104	0.000804	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000104	0.000801	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—XIAP—esophageal cancer	0.000103	0.000796	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ADH1B—esophageal cancer	0.000103	0.000792	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTT1—esophageal cancer	0.000102	0.00079	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP2A6—esophageal cancer	0.000101	0.000781	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000101	0.000778	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.0001	0.000775	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TYMP—esophageal cancer	9.8e-05	0.000757	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	9.76e-05	0.000754	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CTNNA1—esophageal cancer	9.74e-05	0.000753	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL2—esophageal cancer	9.69e-05	0.000749	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	9.63e-05	0.000744	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS1—esophageal cancer	9.58e-05	0.000741	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ENO1—esophageal cancer	9.58e-05	0.000741	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	9.58e-05	0.00074	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP26A1—esophageal cancer	9.53e-05	0.000737	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PSME2—esophageal cancer	9.44e-05	0.00073	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PSME1—esophageal cancer	9.44e-05	0.00073	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—GNG7—esophageal cancer	9.41e-05	0.000727	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALOX15—esophageal cancer	9.29e-05	0.000718	CbGpPWpGaD
Valsartan—ALB—Metabolism—BLVRB—esophageal cancer	9.24e-05	0.000714	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC52A3—esophageal cancer	9.24e-05	0.000714	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PSME1—esophageal cancer	9.05e-05	0.000699	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PSME2—esophageal cancer	9.05e-05	0.000699	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ANXA1—esophageal cancer	9.01e-05	0.000696	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TPI1—esophageal cancer	8.86e-05	0.000685	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTO1—esophageal cancer	8.86e-05	0.000685	CbGpPWpGaD
Valsartan—ALB—Hemostasis—HSPA5—esophageal cancer	8.86e-05	0.000684	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SST—esophageal cancer	8.76e-05	0.000677	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOTCH3—esophageal cancer	8.54e-05	0.00066	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GHRL—esophageal cancer	8.54e-05	0.00066	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	8.51e-05	0.000658	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALDOB—esophageal cancer	8.5e-05	0.000657	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FBXW7—esophageal cancer	8.4e-05	0.000649	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	8.26e-05	0.000638	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.25e-05	0.000637	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GAPDH—esophageal cancer	8.18e-05	0.000632	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP1B1—esophageal cancer	8.15e-05	0.00063	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CRABP1—esophageal cancer	8.11e-05	0.000626	CbGpPWpGaD
Valsartan—ALB—Metabolism—CA1—esophageal cancer	7.86e-05	0.000607	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC10A2—esophageal cancer	7.86e-05	0.000607	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GNG7—esophageal cancer	7.71e-05	0.000596	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP19A1—esophageal cancer	7.66e-05	0.000592	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOTCH2—esophageal cancer	7.66e-05	0.000592	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—BLVRB—esophageal cancer	7.56e-05	0.000585	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC52A3—esophageal cancer	7.56e-05	0.000585	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALDH2—esophageal cancer	7.22e-05	0.000558	CbGpPWpGaD
Valsartan—ALB—Metabolism—CA2—esophageal cancer	7.19e-05	0.000555	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	7.02e-05	0.000543	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—HMOX1—esophageal cancer	6.99e-05	0.00054	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTT1—esophageal cancer	6.87e-05	0.000531	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.86e-05	0.00053	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFBR2—esophageal cancer	6.79e-05	0.000525	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP2A6—esophageal cancer	6.79e-05	0.000525	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	6.77e-05	0.000523	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	6.76e-05	0.000523	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ABCB1—esophageal cancer	6.71e-05	0.000519	CbGpPWpGaD
Valsartan—ALB—Metabolism—ADH7—esophageal cancer	6.68e-05	0.000516	CbGpPWpGaD
Valsartan—ALB—Metabolism—PLCE1—esophageal cancer	6.68e-05	0.000516	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	6.6e-05	0.00051	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ABL1—esophageal cancer	6.56e-05	0.000507	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ENO1—esophageal cancer	6.44e-05	0.000498	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS1—esophageal cancer	6.44e-05	0.000498	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	6.43e-05	0.000497	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC10A2—esophageal cancer	6.43e-05	0.000497	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CA1—esophageal cancer	6.43e-05	0.000497	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SMAD4—esophageal cancer	6.43e-05	0.000497	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PSME2—esophageal cancer	6.35e-05	0.00049	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PSME1—esophageal cancer	6.35e-05	0.00049	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CA2—esophageal cancer	5.88e-05	0.000455	CbGpPWpGaD
Valsartan—ALB—Metabolism—ADH1B—esophageal cancer	5.86e-05	0.000453	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	5.75e-05	0.000444	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—HMOX1—esophageal cancer	5.73e-05	0.000443	CbGpPWpGaD
Valsartan—ALB—Metabolism—TYMP—esophageal cancer	5.6e-05	0.000433	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.54e-05	0.000428	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ABCB1—esophageal cancer	5.5e-05	0.000425	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP1B1—esophageal cancer	5.48e-05	0.000423	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ADH7—esophageal cancer	5.47e-05	0.000423	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLCE1—esophageal cancer	5.47e-05	0.000423	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP26A1—esophageal cancer	5.45e-05	0.000421	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	5.41e-05	0.000418	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALOX15—esophageal cancer	5.31e-05	0.00041	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HIF1A—esophageal cancer	5.26e-05	0.000407	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP19A1—esophageal cancer	5.15e-05	0.000398	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.07e-05	0.000392	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTO1—esophageal cancer	5.06e-05	0.000391	CbGpPWpGaD
Valsartan—ALB—Metabolism—TPI1—esophageal cancer	5.06e-05	0.000391	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KDR—esophageal cancer	5.03e-05	0.000389	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALDOB—esophageal cancer	4.85e-05	0.000375	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ADH1B—esophageal cancer	4.8e-05	0.000371	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOTCH1—esophageal cancer	4.74e-05	0.000366	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS2—esophageal cancer	4.73e-05	0.000365	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HMOX1—esophageal cancer	4.7e-05	0.000363	CbGpPWpGaD
Valsartan—ALB—Metabolism—GAPDH—esophageal cancer	4.67e-05	0.000361	CbGpPWpGaD
Valsartan—ALB—Metabolism—CRABP1—esophageal cancer	4.63e-05	0.000358	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.61e-05	0.000356	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TYMP—esophageal cancer	4.58e-05	0.000354	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ABCB1—esophageal cancer	4.51e-05	0.000348	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CREBBP—esophageal cancer	4.49e-05	0.000347	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP26A1—esophageal cancer	4.46e-05	0.000345	CbGpPWpGaD
Valsartan—ALB—Metabolism—GNG7—esophageal cancer	4.41e-05	0.00034	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALOX15—esophageal cancer	4.34e-05	0.000336	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CREBBP—esophageal cancer	4.3e-05	0.000332	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CREBBP—esophageal cancer	4.25e-05	0.000328	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EGFR—esophageal cancer	4.22e-05	0.000326	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	4.15e-05	0.000321	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTO1—esophageal cancer	4.14e-05	0.00032	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TPI1—esophageal cancer	4.14e-05	0.00032	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALDH2—esophageal cancer	4.13e-05	0.000319	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CA—esophageal cancer	4.04e-05	0.000312	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NOS3—esophageal cancer	4.02e-05	0.00031	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALDOB—esophageal cancer	3.97e-05	0.000307	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTT1—esophageal cancer	3.93e-05	0.000303	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2A6—esophageal cancer	3.88e-05	0.0003	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.87e-05	0.000299	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOS3—esophageal cancer	3.85e-05	0.000297	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GAPDH—esophageal cancer	3.82e-05	0.000296	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS3—esophageal cancer	3.8e-05	0.000294	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CRABP1—esophageal cancer	3.79e-05	0.000293	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS1—esophageal cancer	3.68e-05	0.000284	CbGpPWpGaD
Valsartan—ALB—Metabolism—ENO1—esophageal cancer	3.68e-05	0.000284	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	3.68e-05	0.000284	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—esophageal cancer	3.67e-05	0.000284	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CA—esophageal cancer	3.67e-05	0.000283	CbGpPWpGaD
Valsartan—ALB—Metabolism—PSME1—esophageal cancer	3.63e-05	0.00028	CbGpPWpGaD
Valsartan—ALB—Metabolism—PSME2—esophageal cancer	3.63e-05	0.00028	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GNG7—esophageal cancer	3.61e-05	0.000279	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ERBB2—esophageal cancer	3.6e-05	0.000278	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.41e-05	0.000263	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALDH2—esophageal cancer	3.38e-05	0.000261	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTT1—esophageal cancer	3.21e-05	0.000248	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCND1—esophageal cancer	3.18e-05	0.000246	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2A6—esophageal cancer	3.18e-05	0.000246	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.17e-05	0.000245	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.16e-05	0.000245	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP1B1—esophageal cancer	3.13e-05	0.000242	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1A—esophageal cancer	3.08e-05	0.000238	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—EP300—esophageal cancer	3.05e-05	0.000236	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CREBBP—esophageal cancer	3.01e-05	0.000233	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS1—esophageal cancer	3.01e-05	0.000233	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ENO1—esophageal cancer	3.01e-05	0.000233	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PSME1—esophageal cancer	2.97e-05	0.000229	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PSME2—esophageal cancer	2.97e-05	0.000229	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP19A1—esophageal cancer	2.94e-05	0.000227	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EP300—esophageal cancer	2.93e-05	0.000226	CbGpPWpGaD
Valsartan—ALB—Hemostasis—EP300—esophageal cancer	2.89e-05	0.000224	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NOS3—esophageal cancer	2.7e-05	0.000209	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMOX1—esophageal cancer	2.68e-05	0.000207	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.63e-05	0.000203	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.59e-05	0.0002	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCB1—esophageal cancer	2.58e-05	0.000199	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP1B1—esophageal cancer	2.56e-05	0.000198	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MYC—esophageal cancer	2.55e-05	0.000197	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGFR—esophageal cancer	2.49e-05	0.000193	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—esophageal cancer	2.47e-05	0.000191	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP19A1—esophageal cancer	2.41e-05	0.000186	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CA—esophageal cancer	2.26e-05	0.000175	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMOX1—esophageal cancer	2.2e-05	0.00017	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CA—esophageal cancer	2.17e-05	0.000167	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.16e-05	0.000167	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CA—esophageal cancer	2.14e-05	0.000165	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCB1—esophageal cancer	2.11e-05	0.000163	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—esophageal cancer	2.09e-05	0.000162	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—esophageal cancer	2.07e-05	0.00016	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—EP300—esophageal cancer	2.05e-05	0.000159	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.95e-05	0.000151	CbGpPWpGaD
Valsartan—ALB—Metabolism—CREBBP—esophageal cancer	1.72e-05	0.000133	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.59e-05	0.000123	CbGpPWpGaD
Valsartan—ALB—Metabolism—NOS3—esophageal cancer	1.54e-05	0.000119	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CA—esophageal cancer	1.52e-05	0.000117	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—esophageal cancer	1.41e-05	0.000109	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CREBBP—esophageal cancer	1.41e-05	0.000109	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NOS3—esophageal cancer	1.26e-05	9.75e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—EP300—esophageal cancer	1.17e-05	9.06e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—esophageal cancer	1.15e-05	8.92e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—EP300—esophageal cancer	9.6e-06	7.42e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CA—esophageal cancer	8.67e-06	6.7e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CA—esophageal cancer	7.1e-06	5.49e-05	CbGpPWpGaD
